News from macrogenics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 10, 2013, 02:44 ET

MacroGenics Announces Pricing of Initial Public Offering

 MacroGenics, Inc., today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public...

Sep 19, 2013, 07:00 ET

MacroGenics' Board of Directors Elects Paulo F. Costa as Chairman

 MacroGenics, Inc. today announced its Board of Directors has elected Paulo F. Costa as its new Chairman. The company also announced that Dr....

Aug 20, 2013, 07:00 ET

MacroGenics to Receive $10 Million Milestone Payment from Servier for Dosing the First Patient in a Phase 1 Dose Expansion Trial of MGA271

 MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...

Aug 12, 2013, 07:00 ET

MacroGenics Appoints Jon Wigginton, M.D., as Senior Vice President, Clinical Development

 MacroGenics, Inc. today announced that it has appointed Jon Wigginton, M.D., as Senior Vice President, Clinical Development. Dr. Wigginton...

Jun 03, 2013, 19:13 ET

MacroGenics Presents Phase 1 Data at ASCO Showing Signs of Clinical Benefit for Margetuximab in HER2 Expressing Tumors

 MacroGenics, Inc. announced that results of the first-in-human study of margetuximab were reported during an oral abstract session today at...

May 21, 2013, 07:00 ET

MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer

 MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal...

Jan 07, 2013, 07:25 ET

MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products

MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody...

Sep 20, 2012, 07:00 ET

MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products

 MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's...

Dec 20, 2011, 07:00 ET

MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim

 MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will...

Dec 01, 2011, 07:00 ET

MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug

MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest...

Jun 28, 2011, 12:30 ET

The Lancet Publishes Data from Protege, MacroGenics' Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious...

Jun 23, 2011, 07:00 ET

MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious...

Apr 28, 2011, 13:02 ET

Data Published in Blood Demonstrate Potent Activity of MacroGenics' Proprietary DART™ Technology

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious...

Jan 06, 2011, 06:00 ET

MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients With HER2-Expressing Solid Tumors

 MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and...

Oct 26, 2010, 16:30 ET

MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer

MacroGenics, Inc., a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research...

Oct 26, 2010, 14:50 ET

Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics

Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global alliance to discover, develop and commercialize...

Jul 15, 2010, 06:00 ET

MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding Further Advances DART Platform and Infectious Disease Portfolio

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious...

Jan 07, 2010, 06:00 ET

MacroGenics Appoints New Senior Vice President of Clinical Development

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious...

Jul 13, 2009, 07:00 ET
Jun 23, 2009, 08:21 ET

Paulo F. Costa Joins MacroGenics Board of Directors

MacroGenics, Inc. announced today that Mr. Paulo F. Costa has been elected to the company's Board as an independent director. Mr. Costa is the...